Revolutions Medical Files Four Utility Patents on Breakthrough MRI Imaging Software Technology Acquired in Clear Image Acquisition
Posted on: Monday, 18 June 2007, 15:02 CDT
Revolutions Medical Corporation (OTCBB: RMCP), Mount Pleasant, SC announces that Lowrie, Lando, and Anastasi, LLP (www.ll-a.com) has successfully filed, on its behalf, four utility patents focused on its MRI imaging software technology. These patents were based on the provisional patents filed last June and acquired in the Clear Image Acquisition transaction earlier this year. It is believed that these patents will provide the basis for a family of MRI imaging and search product offerings and also firms up its established intellectual property.
Ron Wheet, CEO of Revolutions Medical Corporation, states, "now we will move forward this summer with extensive continued testing and our goal is to have our new MRI imaging software ready for the Radiologist Society of North America (RSNA) show in Chicago this fall. We are very pleased with this accomplishment in such a short time after our acquisition, and believe these patents will add a great deal of value to our company along with our other intellectual properties."
About Revolutions Medical Corporation
Revolutions Medical Corporation is committed to continually developing and distributing new products and tools to the medical industry, whether internally or through acquisitions. Its goals are to make health care safer and less expensive by reducing risks and cutting time and expenses. Its products include the RevVac safety syringe, safety blood drawing device and safety IV catheter. The world market for safety-engineered medical devices (SEMDs) is projected to exceed 2 billion this year and is forecasted to maintain a 20% annual growth rate in the near term. Revolutions Medical also provides software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software includes sorting of images, color, 3D, and automatic segmentation of images. These tools will enhance the physician's diagnostic confidence in an industry that is growing at 10% - 15% (more than 25 million procedures) per year with a worldwide market potential for these tools that exceed $3.5 billion.
Safe Harbor
Forward-looking statements made in this release are made pursuant to the "safe-harbor" provision of the Private Securities Litigation Reform Act of 1995. Forward-looking statements made by Revolutions Medical Corporation are not a guarantee of future performance. This news release includes forward-looking statements, including with respect to the future level of business for the parties. These statements are necessarily subject to risk and uncertainty.
Actual results could differ materially from those projected in these forward-looking statements as a result of certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Revolutions Medical Corporation, and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, properly price, retain and successfully complete projects, and changes in products and competition.
Source: Business Wire
Related Articles
- Cardio Vascular Medical Device Launches Corporate Website
- Revolutions Medical Corporation Moves Forward on a PACS Delivery Platform for Its Breakthrough MRI Software Technologies
- Revolutions Medical Announces Plans to Move Forward With Strategic Product Development To Test and Evaluate Its New Breakthrough MRI Software Technology
- Companion Technologies Adds Web Interface for Medical Patient Statements
- St. Jude Medical Announces FDA Clearance of EnSite(R) System 6 Software for Cardiac Mapping and Navigation
- Boothroyd Dewhurst Sells Corporate License for DFMA Software to Plug Power Inc.
- MannKind Corporation Announces Positive Results From a Phase 2b Dose-Ranging Study of Technosphere(R) Insulin in Patients With Type 2 Diabetes
- Chevron Corporation and Unocal Corporation Announce Preliminary Results of Elections for Merger Consideration
- Celgene Corporation First Quarter Results Deliver Record Operating Performance and Key Clinical and Regulatory Progress
User Comments (0)

RSS Feeds